<p>Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought RanbaxyLaboratories Ltd.<br><br>The world's fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.<br><br>"Decisions are being made to either close or divest some of our manufacturing facilities," a Sun Pharma spokesman said in an emailed statement.<br><br>"Currently, the Ireland facility has been identified for divestment."<br><br>Following the completion of the Ranbaxy acquisition in March this year, Sun Pharma last month reported one-off integration-related costs of 6.85 billion rupees ($102.86 million) for the quarter ended June.<br><br>It has warned that revenue may remain flat or decline this fiscal year, as it faces supply constraints at one of its own plants in Gujarat.</p><p>(Reuters)</p>
